Calithera Biosciences, Inc. Prices Public Offering of 12,500,000 shares of Common Stock
June 18 2019 - 11:00PM
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage
biotechnology company focused on discovering and developing novel
small molecule drugs for the treatment of cancer and other
life-threatening diseases, today announced the pricing of its
previously announced underwritten public offering of 12,500,000
shares of its common stock at a price to the public of $4.00 per
share. Gross proceeds to Calithera from the offering are
expected to be $50,000,000, before deducting underwriting discounts
and commissions and estimated offering expenses. All of the
shares of common stock are being offered by Calithera. In addition,
Calithera has granted the underwriters a 30-day option to purchase
up to 1,875,000 of additional shares of common stock at the public
offering price. The offering is expected to close on June 21,
2019, subject to customary closing conditions.
SVB Leerink, Wells Fargo Securities and William
Blair are acting as joint book-running managers for the
offering.
A shelf registration statement relating to the
offered shares of common stock was filed with the Securities and
Exchange Commission (SEC), and was declared effective. A
preliminary prospectus supplement and accompanying prospectus
relating to the offering have been filed with the SEC and are
available on the SEC’s website, located at www.sec.gov.
Copies of the final prospectus supplement and accompanying
prospectus related to the offering may be obtained, when available,
from SVB Leerink LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, Massachusetts 02110, by telephone at
800-808-7525, ext. 6132 or by email at syndicate@svbleerink.com;
Wells Fargo Securities, LLC, Attention: Equity Syndicate
Department, 375 Park Avenue, New York, New York 10152 at
800-326-5897 or email a request to cmclientsupport@wellsfargo.com;
or William Blair & Company, L.L.C., Attention: Prospectus
Department, 150 North Riverside Plaza, Chicago, IL 60606, or by
telephone at 800-621-0687 or email at
prospectus@williamblair.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
Investor Relations Contact: Jennifer McNealey
ir@Calithera.com 650-870-1071 |
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Apr 2024 to May 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From May 2023 to May 2024